In contrast, observations that GPR55 tissue expression and circulating levels of LPI are raised in conditions where there is heightened cardiovascular risk (such as obesity and metabolic syndrome33); that cardiac LPI levels rise during asphyxia‐induced myocardial ischemia,24, 25 and that the GPR55 antagonist CBD reduces myocardial infarct size in rats in vivo9, 46 all point to a potential detrimental role for LPI/GPR55 in cardiovascular pathologies such as AMI. The gene discussed is GPR55; the disease is Obesity.